Melatoninergic receptor agonists and antagonists: Pharmacological aspects and therapeutic perspective;Agonistes et antagonistes des récepteurs mélatoninergiques: Effets pharmacologiques et perspectives thérapeutiques

Annales Pharmaceutiques Francaises

Volumn 63, Issue 6, 2005, Pages 385-400

  Guardiola Lemaitre, B ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

Agonist; Antagonist; Innovation; Melatonin; Therapeutic

Indexed keywords

MELATONIN; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; MELATONINERGIC RECEPTOR AGONIST; MELATONINERGIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

BASAL METABOLIC RATE; CENTRAL NERVOUS SYSTEM; CIRCADIAN RHYTHM; DEPRESSION; DRUG EFFECT; ENDOCRINE FUNCTION; HALF LIFE TIME; HUMAN; OBESITY; PINEAL BODY; REDUCTION; REVIEW; SEASONAL AFFECTIVE DISORDER; SEASONAL VARIATION; SLEEP; SUPRACHIASMATIC NUCLEUS; TRANQUILIZING ACTIVITY;

EID: 29144487131     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0003-4509(05)82308-9     Document Type: Review

References (31)

1. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori W. Isolation of melatonin, the pineal gland factor that lightens melanocytes. J Amer Chem Soc 1958; 80: 2587.
2. Klein DC, Weller JL. Indole metabolism in the pineal gland: a circadian rhythm in N-acetyltransferase. Science 1970; 269: 1093-5.
3. Launay JM, Lemaitre BJ, Dreux C, Hartmann L, Da Prada M. Melatonin synthesis by rabbit platelets. Life Sci 1982; 31: 1487-94.
4. Lemaitre BJ, Hartmann J. Preparation of anti-melatonin antibodies and antigenic properties of the molecule. J Immunol Methods 1980; 32: 339-47.
5. Lemaitre BJ, Bouille J, Hartmann J. Variations of urinary melatonin excretion in humans during the first 30 years of life. Clin Chim Acta 1981; 110: 77-82.
6. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre B, Hagan RM, Krause DN, Sugden D et al. Melatonin receptors 1998. In The IUPHAR Compendium of Receptor Characterization and Classification, Girdlestone D. (ed.), IUPHAR Media, London, pp 188-93.
7. Nosjean O, Ferro M, Coge F, Beauverger M, Henlin JM, Lefoulon F et al. Identification of melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem 2000; 275: 31311-7.
8. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 1997; 12: 528-31.
9. 1aβ melatonin receptor. Biochem Biophys Res Commun 1997; 239: 418-23.
10. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Frontiers in Bioscience 2003; 8: d1093-108.
11. Morgan PJ, Barrett P, Howell E, Helliwell R. Melatonin receptors: localization, molecular pharmacology and physiological significance. Neurochem Int 1994; 24: 101-46.
12. Pang SF, Dubocovich ML, Brown GM. Melatonin receptors in peripheral tissues: a new area of melatonin research. Biol Signals 1993; 2 (4): 177-80.
13. Reiter RJ, Dun-Xian T. Melatonin: reducing intracellular hostilities. The Endocrinologist, 2004; 14: 222-8.
14. Gauer F, Masson-Pévet M, Pévet P. Melatonin receptor density is regulated in rat pars tuberalis and suprachiasmatic nuclei by melatonin itself. Brain Res 1993; 602: 153-6.
15. Schuster C, Gauer F, Malan A, Recio J, Pévet P, Masson-Pévet M. The circadian clock, light/dark cycle and melatonin are differentially involved in the expression of daily and photoperiodic variations in mt(1) melatonin receptors in the Siberian and Syrian hamsters. Neuroendocrinology 2001; 74 (1): 55-68.
16. Gauer F, Masson-Pévet M, Skene DJ, Vivien-Roels B, Pévet P. Daily rhythms of melatonin binding sites in the rat pars tuberalis and suprachiasmatic nuclei; evidence for a regulation of melatonin receptors by melatonin itself. Neuroendocrinobgy 1993; 57: 120-6.
17. Laitinen JT, Viswanathan M, Vakkuri O, Saavedra JM. Differential regulation of the rat melatonin receptors: selective age-associated decline and lack of melatonin-induced changes. Endocrinology 1992; 130: 2139-44.
18. Stelhe JH, Von Gall C, Korf HN. Melatonin: a clock output, a clock input. J Neuroendocrinol 2003; 15: 383-9.
19. Buijs RM, Kalsbeek A. Hypothalamic integration of central and peripheral clocks. Nature Reviews, Neuroscience 2001; 2: 521-6.
20. Lesieur D, Leclerc V, Chavatte P, Marot C, Renard P, Guardiola-Lemaitre B. La mélatonine, prototype pertinent pour l'innovation thérapeutique. Thérapie 1998; 53: 429-37.
21. Yous S, Lesieur D, Andrieux J, Howell T, Morgan P, Guardiola-Lemaitre B. Novel naphtalenic ligands with high affinity for the melatonin receptor. Am J Med Chem 1992; 35: 1484-6.
22. Masson-Pevet M, Recio J, Guerrero HY, Mocaer E, Delagrange P, Guardiola-Lemaitre B et al. Effects of two melatonin analogues, S 20098 and S 20928, on melatonin receptors in the pars tuberalis of the rat. J Pineal Res 1998; 25: 172-6.
23. Loo H, Dalery J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomélatine, melatoninergic agonist and selective 5-HT2C receptor antagonist, in the treatment of major depressive disorders. Encephale 2002; 28: 356-62.
24. Armstrong SM, Redman JR. Melatonin and circadian rhythmicity. In Melatonin: Biosynthesis, Physiological Effects and Clinical Applications, Yu H.S. & Reiter R.J. (eds.), 1993 CRC Press, Boca Raton, USA, 187-224.
25. Armstrong SM, McNulty OM, Redman JR, Guardiola-Lemaitre B. Successful use of S 20098 and melatonin in an animal model of delayed sleep phase syndrome (DSPS). Pharmacol Biochem Behav 1993; 46: 45-9.
26. Redman JR, Guardiola-Lemaitre B. The melatonin agonist, S 20098: effects on the rat circadian system. Melatonin and the pineal gland - from basic science to clinical application. Elsevier Publisher 1993. Y. Touitou, J. Arendt and P. Pevet, editors. pp 127-30.
27. Touitou Y, Bogdan A, Auzéby A, Selmaoui B. Mélatonine et vieillissement. Thérapie 1998; 53: 473-8.
28. Koster-Van Hoffen GC, Mirmiran M, Bos NPA, Witting W, Delagrange P, Guardiola-Lemaitre B. Effects of a novel melatonin analog on circadian rhythms of body temperature and activity in young, middle-aged and old rats. Neurobiology of aging 1993; 14: 565-9.
29. Agomélatine. Drugs of the Future 2003; 28 (1): 7-13.
30. Ostrowska Z, Buntner B, Zwirska-Korczala K, Marek B, Nowak M. Circadian oscillation of melatonin, gonadotropins, sex hormones and SHBG in post-menopausal women showing android and gynoid type obesity. Endocr Regul 1996; 30: 133-4.
31. Le Gouic S, Delagrange P, Atgie C, Nibbelink M, Hanoun N, Casteilla L et al. Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the Garden Dormouse. Int J Obes Relat Metab Disord 1996; 20: 661-7.